SCHEMBL5254183

SCHEMBL5254183

NC(=O)C(O)CN1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
MAPT P10636 4/20 0.46
ATM Q13315 3/20 0.46
ANPEP P15144 1/20 0.44
ERAP2 Q6P179 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 3/20 0.39
HPGD P15428 1/20 0.39
GAA P10253 1/20 0.35
POLB P06746 1/20 0.35
MITF O75030 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
GFER P55789 1/20 0.35
PAX8 Q06710 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CHRM2 P08172 1/20 0.35
ADRA2B P18089 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5243859 1.00 MEN1 (0.50) MEN1KMT2AMAPTATMANPEP
SCHEMBL5243190 0.98 MEN1 (0.54) MEN1KMT2AMAPTATMANPEP
SCHEMBL19532370 0.98 MEN1 (0.54) MEN1KMT2AMAPTATMANPEP
SCHEMBL4489543 0.81 USP2 (0.57) MEN1KMT2AMAPTATMANPEP
SCHEMBL21806105 0.81 SMN1; SMN2 (0.42) MEN1KMT2AMAPTANPEPERAP2
SCHEMBL4150403 0.81 USP2 (0.57) MEN1KMT2AMAPTATMANPEP
SCHEMBL4486391 0.79 RAB9A (0.34) MEN1KMT2AALDH1A1RAB9ACYP2C19
SCHEMBL472331 0.77 MEN1 (0.56) MEN1KMT2AMAPTATMANPEP
SCHEMBL5240812 0.77 KDM4E (0.62) MEN1KMT2AMAPTL3MBTL1HSD17B10
SCHEMBL4637391 0.76 ANPEP (0.52) MEN1KMT2AMAPTATMANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2476667-A2 Aminoheteroaryl compounds as protein kinase inhibitors Sugen, Inc. (US) 2012-07-18 EP claimed
EP-1653946-A4 GEOMETRICALLY RESTRICTED 3-CYCLOPENTYLIDENE-1,3-DIHYDROINDOL-2-ONES AS POTENT PROTEIN KINASE INHIBITORS SUGEN INC (US) 2007-04-04 EP claimed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 US claimed
JP-2007501229-A 2007-01-25 JP claimed
US-7105562-B2 Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors SUGEN, INC. (US) 2006-09-12 US claimed
JP-2006519232-A 2006-08-24 JP claimed
EP-1653946-A2 GEOMETRICALLY RESTRICTED 3-CYCLOPENTYLIDENE-1,3-DIHYDROINDOL-2-ONES AS POTENT PROTEIN KINASE INHIBITORS Sugen, Inc. (US) 2006-05-10 EP claimed
EP-1603570-A2 AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS Sugen, Inc. (US) 2005-12-14 EP claimed
WO-2005016875-A2 GEOMETRICALLY RESTRICTED 3-CYCLOPENTYLIDENE-1,3-DIHYDROINDOL-2-ONES AS POTENT PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2005-02-24 WO claimed
US-20050038066-A1 Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors SUGEN, INC. 2005-02-17 US claimed
US-20050009840-A1 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. 2005-01-13 US claimed
WO-2004076412-A2 AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2004-09-10 WO claimed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP claimed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO claimed
CN-113181362-B Medicament for preventing and/or treating amyotrophic lateral sclerosis 国立大学法人京都大学 2023-06-13 CN disclosed
US-4218487-A AMINO SUGAR, AMINO ACID, POLYOL OR WATER GIVAUDAN CORPORATION (US) 1980-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 MEN1 4419/4885KMT2A 1573/4885MAPT 2035/4885
US-20050009840-A1 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer MET, ERBB2, CDK4 MEN1 783/4885KMT2A 430/4885MAPT 2514/4885
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors MET, MAP4K1, MAP4K2 MEN1 1141/4885KMT2A 1170/4885MAPT 2035/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 MEN1 2591/4885KMT2A 1923/4885MAPT 3167/4885
US-20050038066-A1 Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors CKS2, ABL1, ERBB2 MEN1 3948/4885KMT2A 1486/4885MAPT 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.